Climb Bio Inc.
CLYM | NASDAQ
$10.24
-$0.09 (-0.87%)
At close: Oct 30, 2026, 3:59 PM ET
$10.25
+$0.01 (+0.10%)
Pre-market:
Nov 2, 2026, 4:36 AM ET
Company Profile
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
Key Executives
| Name | Position |
|---|---|
| Aoife Brennan BCh MMSc | Chief Executive Officer, President & Director |
| Adam Villa | Senior Vice President of Technical Operations |
| Ashley Jones | Senior Vice President of People & Workforce Strategy |
| Chandra Adams | Senior VP, General Counsel & Secretary |
| Edgar D. Charles | Chief Medical Officer |
| Janaki Subramanyam | Vice President & Head of Regulatory Affairs |
| Perrin Wilson | Chief Business Officer |
| Susan Altschuller | CFO & Principal Accounting Officer |
| Theresa Donegan | Vice President & Head of Quality |
Climb Bio Inc.
| Country | United States |
| IPO Date | Aug 10, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | Aoife Brennan BCh MMSc |
Contact Details
20 William Street Wellesley Hills,
Massachusetts 02481 United States
Stock Details
| Ticker Symbol | CLYM |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001768446 |
| CUSIP Number | 28658R106 |
| ISIN Number | US28658R1068 |
| SIC Code | n/a |
Add to Watchlist
Select watchlists to add or remove CLYM